Actively Recruiting
Evaluating WIN378 for Safety and Effectiveness in Adults With Moderate to Severe Asthma Using Randomized, Double-Blind Placebo-Controlled Methods
Led by Windward Bio · Updated on 2026-10-21
600
Participants Needed
73
Research Sites
7 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating WIN378, an ultra-long-acting medicine, in adults with moderate to severe asthma to assess its safety, how the body processes it, and its effects on lung function and asthma control. This global Phase 2 study has two parts Part A focuses on finding the right dose of WIN378, while Part B tests the chosen doses against placebo in adults with severe uncontrolled asthma to evaluate reduction in asthma flare-ups and improvements in quality of life. Participants receive WIN378 or placebo via subcutaneous injections. Part A tests three doses to understand pharmacokinetics, safety, and efficacy, including markers of inflammation in breath and blood, lung function, and asthma control. An interim analysis selects two doses for Part B, which compares these doses against placebo over 24 weeks to assess the annualized asthma exacerbation rate, lung function improvements, asthma control, and safety. During the study, participants undergo regular assessments including lung function tests, blood and breath tests for inflammation, questionnaires on asthma symptoms and quality of life, and monitoring for adverse events. Researchers track drug levels in the body and immune responses over about 60 weeks in Part A and 24 weeks after last dose in Part B. The total participation duration extends up to nearly five years, with continuous safety and efficacy monitoring.
CONDITIONS
Brief Title
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
Research Team
A
Ayshea Kring
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here